SEC Form 4	
------------	--

 $\Box$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).
---

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burd	en				
hours per response:	0.5				

1. Name and Address of Reporting Person <sup>*</sup> SCP Vitalife Partners II LP			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>ReWalk Robotics Ltd.</u> [ RWLK ]		tionship of Reporting all applicable) Director	Perso X	n(s) to Issuer 10% Owner	
(Last) 7 GREAT VAL	(First) LEY PARKWA	(Middle) Y, SUITE 190	3. Date of Earliest Transaction (Month/Day/Year) 06/26/2017		Officer (give title below)		Other (specify below)	
(Street) MALVERN PA 19355-1446 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Form filed by One Form filed by More Person	Report	ting Person	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)	
Ordinary Shares, par value NIS 0.01 per share	06/26/2017		S <sup>(1)</sup>		27,759	D	\$3	1,055,133	<b>D</b> <sup>(2)</sup>		
Ordinary Shares, par value NIS 0.01 per share	06/27/2017		S <sup>(1)</sup>		37,459	D	\$3.0931 <sup>(3)</sup>	1,017,674	<b>D</b> <sup>(2)</sup>		

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3A. Deemed Execution Date, 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities 5. Number of 8. Price of Derivative 9. Number of 3. Transaction 10. Execution Date, if any (Month/Day/Year) 8) Conversion Date (Month/Day/Year) derivative Ownership Derivative Security (Instr. 5) or Exercise Securities Form: Price of Securities Underlying Beneficially Direct (D)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		Transaction of Code (Instr. Derivative		Transaction Code (Instr. Derivative 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		Expiration Date (Month/Day/Year) eed 3, 4		tion Date Amount of		Amount of Securities Underlying Derivative Security (Instr. 3)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

1. Name and Address of Reporting Person\*

### SCP Vitalife Partners II LP

(Last)	(First)	(Middle)
7 GREAT VAL	LEY PARKWAY,	SUITE 190
(Street)		
MALVERN	PA	19355-1446
(City)	(State)	(Zip)
1. Name and Addre	ess of Reporting Perso	on <sup>*</sup>
<u>SCP Vitalife</u>	II Associates,	<u>L.P.</u>
(Last)	(First)	(Middle)
7 GREAT VAL	LEY PARKWAY,	SUITE 190
(Street)		
MALVERN	PA	19355-1446
(City)	(State)	(Zip)
1. Name and Addre	ess of Reporting Perso	on*
<u>SCP Vitalife</u>	<u>II GP, Ltd.</u>	
(Last)	(First)	(Middle)
7 GREAT VAL	LEY PARKWAY	

SUITE 190		
(Street)		
MALVERN	PA	19355-1446
(City)	(State)	(Zip)
1. Name and Address of CHURCHILL V		
(Last)	(First)	(Middle)
7 GREAT VALLEY	PARKWAY, SUITE	190
(Street)		
MALVERN	PA	19355-1446
(City)	(State)	(Zip)
1. Name and Address of LUDOMIRSKI		
(Last)	(First)	(Middle)
7 GREAT VALLEY	PARKWAY, SUITE	190
(Street)		
MALVERN	PA	19355-1446
(City)	(State)	(Zip)

### Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016.

2. The Ordinary Shares are directly held by SCP Vitalife Partners II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.0000 to \$3.2000, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

<u>/s/ Winston J. Churchill,</u> attorney-in-fact

06/28/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.